The PPP Unit is at the Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB-UAB) and counts with the necessary facilities for the design, production and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, leaded by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic,X-ray crystallography, and the Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.
Counts with a laboratory perfectly equipped for the bioproduction of proteins, other with all the necessary equipment for the molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.
The PPP Unit is also applying for the ISO9001 certification forstandard quality control system.
FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
|Title||Fundin: Organism||Call: Funding source||Role|
|GA: 720942||SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry||Unión Europea (Comisión Europea)||H2020-NMBP-2016-2017||Coordinator|
|SAF2017-90810-REDI||Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II||Agencia Estatal de Investigación (AEI)||Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017||Coordinator|
|Ref||Title||Funding Organism||Unit Role|
|PI15/00272||Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer.||Instituto de Salud Carlos III||Participant|
|BIO2013-41019-P||ENGINEERING OF PROTEIN NANOPARTICLES FOR THE DIRECT DELIVERY OF THERAPEUTIC PROTEINS AND NUCLEIC ACIDS||MINECO||Participant|
|2014SGR-132||Basic and Applied Microbiology||AGAUR||Participant|
|BIO2016-76063-R||DEVELOPMENT OF NONOSTRUCTURED PROTEIN TOXINS AND POISONS FOR THE TREATMENT OF CXCR4 + CANCERES||MINECO||Working package|
|RTC-2014-2207-1||TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases||MINECO||Participant|
|Marato 416/C/2030TV32013-132031||Genotoxic nanoparticles targeting colorectal cancer stem cells||Marato TV3||Participant|
Researchers of NANBIOSIS U18 Nanotoxicology Unit and U1. Protein Production Platform (PPP) at the Biomedical Research Institute of Sant Pau (IIB Sant Pau), of the Hospital of Santa Creu i Sant Pau, of the Universitat Autònoma de Barcelona (UAB), the Superior Council of Scientific Research (CSIC) and the Center for Biomedical Research in Network (CIBER) have published an article in one of the most prestigious international scientific journals in the field of Molecular Medicine, EMBO Molecular Medicine. This article demonstrates the efficacy of the nanopharmaceutical that selectively removes metastatic stem cells in animal models of colon cancer. The new drug works like a[...]
On October 24th-26th, Aula Científica, in collaboration with IBB, organizes a theorical and practical course on “Recombinant proteins production: optimization strategies“. Some researchers of NANBIOSIS Unit1 Protein Production Platform (PPP), will transmit their knowhow and experience to the attendees, as José Luis Corchero, Rosa Mendoza Moreno and Neus Ferrer Miralles, Scientific Director of the Protein production planform of ICTS NANBIOSIS. The course is aimed at researchers and laboratory technicians from universities, hospitals, companies and research centers who are interested in the expression, production and purification of recombinant proteins with de objectives of analyze and design strategies for the improvement in the expression,[...]
Researchers of NANBIOSIS U1. Protein Production Platform (PPP), organize a course on production of recombinant proteins together with Aula Científica whose objective is to analyze and design strategies for the improvement in the expression, production and purification of recombinant proteins in heterologous systems. For further information[...]
The general consul of France in Barcelona, Mr. Cyril Piquemal visited the IBB UAB facilities last July 18, to find out about the research that is being carried out and, in particular, explore possible collaborations in nano-pharmacy development projects. During the visit, the Consul of France in Barcelona was received by Màrius Martínez, Vice President of International Relations at the UAB; Maite Paramio, Deputy Vice President; Ivan Martínez, vice president of Research; Salvador Ventura, director of the Institute of Biotechnology and Biomedicine, and Antonio Villaverde, head of the IBB Nanotechnology Unit-NANBIOSIS U1. Protein Production Platform (PPP) Next, the mayor visited[...]
Nanoligent, S.L., the company stablished on March 2017 by professors Dr. A. Villaverde and Dra. E. Vázquez from NANBIOSIS Unit 1, professor Dr. M. Mangués from NANBIOSIS Unit 18, and entrepreneur Dr. M. Rodríguez is highlighted in la Vanguardia. More information here &nbs[...]
Researchers of NANBIOSIS Unit 1 and NANBIOSIS Unit 18, led by Prof Antoni Villaverde have published the article “Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin” at SMALL journal. Under the unmet need of efficient tumor‐targeting drugs for oncology, a recombinant version of the plant toxin ricin (the modular protein T22‐mRTA‐H6) is engineered to self‐assemble as protein‐only, CXCR4‐targeted nanoparticles. The soluble version of the construct self‐organizes as regular 11 nm planar entities that are highly cytotoxic in cultured CXCR4+ cancer cells upon short time exposure, with a determined IC50 in the nanomolar order of magnitude. T[...]
Scientists of NANBIOSIS Units U1. Protein Production Platform (PPP), and U18. Nanotoxicology Unit, have recently published an article titlled “Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs” in the Journal of Controlled Release. Loading capacity and drug leakage from vehicles during circulation in blood is a major concern when developing nanoparticle-based cell-targeted cytotoxics. To circumvent this potential issue it would be convenient the engineering of drugs as self-delivered nanoscale entities, devoid of any heterologous carriers. In this context, we have here engineered potent protein toxins, namely segments of the diphtheria toxin and the Pseudomonas aeruginosa exotoxin as self-assembling, self-delivered therapeutic materials targeted to CXCR4+ cancer stem cells. The systemic administration of both nanostructured drugs in a[...]
Sustained release of drug delivery systems (DDS) has the capacity to increase cancer treatment efficiency in terms of drug dosage reduction and subsequent decrease of deleterious side effects. In this regard, many biomaterials are being investigated but none offers morphometric and functional plasticity and versatility comparable to protein-based nanoparticles (pNPs). Researchers of NANBIOSIS units 1 and 18 are co-authors of an article publish by Journal of Controlled Release in which it is described a new DDS by which pNPs are fabricated as bacterial inclusion bodies (IB), that can be easily isolated, subcutaneously injected and used as reservoirs for the sustained release of targeted pNPs. Our approach combines t[...]